Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 12/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1708822 | 0.81 | KMT2A (0.57) | MAP4K1CYP3A4ABL1L3MBTL1CFTR | |
| SCHEMBL5321641 | 0.80 | MAP2K1 (0.39) | MAP2K2MAP2K1L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL5065113 | 0.79 | PDK2 (0.47) | MAP4K1CYP3A4ABL1L3MBTL1CFTR | |
| SCHEMBL3806699 | 0.79 | MAPT (0.51) | MAP4K1CYP3A4ABL1L3MBTL1CFTR | |
| SCHEMBL1853218 | 0.79 | ALDH1A1 (0.46) | MAP4K1CYP3A4ABL1L3MBTL1CFTR | |
| SCHEMBL7903905 | 0.79 | MAP2K2 (0.41) | MAP2K2MAP2K1L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL24340115 | 0.79 | PDK2 (0.47) | CYP3A4MAP2K2MAP2K1L3MBTL1ALDH1A1 | |
| SCHEMBL2327264 | 0.79 | KDM4E (0.41) | CFTRALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL17774972 | 0.78 | MAP4K1 (0.44) | MAP4K1CYP3A4ABL1L3MBTL1CFTR | |
| SCHEMBL1477538 | 0.78 | MAP2K2 (0.49) | MAP2K2MAP2K1L3MBTL1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | SGX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | SGX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | SGX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| EP-2134179-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7626021-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7626021-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7626021-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| EP-1803452-A1 | ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-20060089392-A1 | Ester derivatives and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, TTK, MAP3K19 | MAP4K1 19/4885CYP3A4 3559/4885ABL1 141/4885 |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | MAP3K20, TTK, MAP3K19 | MAP4K1 19/4885CYP3A4 3559/4885ABL1 141/4885 |
| US-20060089392-A1 | Ester derivatives and medicinal use thereof | MTTP, CETP, LIPA | MAP4K1 2876/4885CYP3A4 449/4885ABL1 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.